OrphoMed Announces Late-breaking Plenary Session Presentation of New Preclinical Data for ORP-101 in IBS-D at Digestive Disease Week 2017
Presentation Highlights IBS-D Data for ORP-101, a Novel Partial μ Agonist κ Antagonist that Avoids Typical Pancreatitis, Sphincter of Oddi Spasm Adverse Events
May 7, 2017
SAN FRANCISCO, CA– OrphoMed, Inc., a biopharmaceutical company developing first-in-class dimer therapeutics, today announced new preclinical data on its lead drug candidate ORP-101 at Digestive Disease Week® (DDW) 2017. The data are being presented during a late-breaking plenary session today, May 7, 2017 beginning at 3:00 p.m. CT at McCormick Place in Chicago, IL.
During today’s presentation, Dr. Pankaj Jay Pasricha, M.D., Director of the Johns Hopkins Center for Neurogastroenterology, highlighted new data from a preclinical study of ORP-101, a partial μ agonist/κ antagonist. These data demonstrate that ORP-101 has the potential to be a more effective and safer therapeutic option than the full μ agonist eluxadoline for IBS-D.
“We are excited by the data from the preclinical study led by Dr. Pasricha, showing the potential for ORP-101 to have the best efficacy and safety profile among therapies for treating IBS-D,” said Nikhilesh Singh, Ph.D., Cofounder and Chief Executive Officer of OrphoMed. “This robust set of data supports advancing ORP-101 into the clinic as we execute our development plans for our novel, potential best-in-class dimer therapeutic.”
A copy of the DDW 2017 presentation is available on OrphoMed’s website at www.orphomed.com. Key highlights include:
- ORP-101 produces a dose-dependent decrease in fecal output in stressed mice model
- ORP-101 simultaneously attenuates GI motility and abdominal pain
- ORP-101 attenuates hyperalgesic abdominal pain more than eluxadoline
- ORP-101 relaxes the sphincter of Oddi, reducing pressure more than eluxadoline
- ORP-101 does not impair gastric emptying, as eluxadoline does
Irritable Bowel Syndrome with Diarrhea (IBS-D) is a chronic and debilitating condition characterized by recurrent abdominal pain or discomfort and altered bowel function. Approximately 28 million individuals in the United States and European Union are affected by IBS-D. Unfortunately, about 57% of patients experienced symptoms daily, 25% weekly and 14% monthly and additional treatment option urgently are needed to manage this chronic condition.
About OrphoMed, Inc.
OrphoMed is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class dimer therapeutics for patients with gastrointestinal disorders. Leveraging its proprietary dimer platform technology, OrphoMed is advancing ORP-101, a potential best-in-class buprenorphine dimer in clinical development for the treatment of IBS-D, and its pipeline of additional dimer conjugates. For more information please visit www.orphomed.com.
Gregory L. Beyer